Brain network connectivity alterations represent a hallmark of progressive supranuclear palsy (PSP), reflecting the characteristic tau pathology that disrupts both subcortical-cortical circuits and distributed brain networks. This page examines the functional neuroimaging findings, circuit-level mechanisms, and clinical correlations that define network dysfunction in PSP.
Progressive supranuclear palsy (PSP) is a 4-repeat tauopathy characterized by akinesia, vertical gaze palsy, postural instability, and cognitive decline. The disease involves selective vulnerability of subcortical nuclei, including the substantia nigra, globus pallidus, subthalamic nucleus, and brainstem reticular formation. These structures form critical nodes in motor and cognitive networks, and their degeneration produces distinctive patterns of functional connectivity disruption that can be visualized using resting-state functional MRI (rs-fMRI). [1]
Unlike Alzheimer's disease, which shows early default mode network disruption, PSP demonstrates predominant involvement of subcortical-cortical loops, particularly the basal ganglia-thalamo-cortical circuits and brainstem tegmental networks. These network changes provide insights into disease pathophysiology and may serve as biomarkers for diagnosis and disease progression monitoring. [2]
In PSP, the default mode network (DMN) shows complex patterns of connectivity change. Studies have demonstrated both increased and decreased connectivity depending on the disease stage and specific subregions examined:
The pattern differs from Parkinson's disease, where DMN changes are more subtle and predominantly involve hippocampal-cortical connections. In PSP, the relative preservation of DMN integrity early in disease distinguishes it from AD, where DMN disruption is a cardinal early feature. [6]
The salience network, comprising the anterior cingulate cortex, anterior insula, and subcortical structures, shows marked disruption in PSP:
The salience network's role in switching between the DMN and central executive networks is particularly relevant to PSP, as patients demonstrate impaired task-switching and cognitive set-shifting that correlates with network dysfunction. [9]
The central executive network (CEN), involving dorsolateral prefrontal cortex and posterior parietal cortex, shows reduced connectivity in PSP, particularly in patients with prominent frontal cognitive impairment:
The motor circuit of the basal ganglia-thalamo-cortical loop shows profound dysfunction in PSP. Unlike Parkinson's disease, where dopaminergic degeneration drives circuit abnormalities, PSP involves direct tau pathology within the basal ganglia nuclei themselves:
The direct and indirect pathways both show dysfunction in PSP, but with a pattern distinct from PD. PSP demonstrates more prominent involvement of the direct pathway (D1-MSN) and greater pallidal output abnormalities, contributing to the axial rigidity and postural instability that characterize the disorder. [15]
Beyond motor circuits, the prefrontal circuits of the basal ganglia-thalamo-cortical system show substantial dysfunction:
The thalamus serves as a critical relay in basal ganglia-cortical circuits and shows prominent connectivity changes in PSP:
The midbrain reticular formation and associated structures show distinctive connectivity patterns in PSP:
The "Hummingbird sign" on midbrain sagittal MRI reflects atrophy of structures including the reticular formation, and functional connectivity studies confirm that this anatomically visible degeneration correlates with network-level dysfunction. [25]
Lower brainstem structures also demonstrate connectivity alterations:
The brainstem-cerebellar network shows combined involvement in PSP:
While PSP and PD both involve basal ganglia dysfunction, network-level changes differ substantially:
| Feature | PSP | Parkinson's Disease |
|---|---|---|
| Primary network involvement | Subcortical-cortical loops | Cortico-striatal loops |
| Basal ganglia pattern | Global dysfunction | Differential (D1 vs D2 pathway) |
| Brainstem networks | Prominent early involvement | Later involvement |
| DMN changes | Relatively preserved early | Progressive disruption |
| Salience network | Early dysfunction | Variable |
Both disorders demonstrate:
PSP and CBS share some network-level features but show important differences:
The network patterns in PSP contrast sharply with AD:
Resting-state connectivity metrics show promise for PSP diagnosis:
Longitudinal connectivity studies demonstrate progressive network disruption:
Network-based biomarkers may help predict clinical outcomes:
The classic PSP phenotype demonstrates:
This phenotype shows:
Patients with prominent cortical symptoms demonstrate:
This variant shows:
Understanding network dysfunction informs therapeutic strategies:
Emerging therapeutic approaches target network-level dysfunction:
Brain network connectivity changes in PSP reflect the characteristic subcortical and brainstem distribution of tau pathology. The basal ganglia-thalamo-cortical circuits show profound dysfunction, while relative preservation of the default mode network distinguishes PSP from Alzheimer's disease. Brainstem network alterations correlate with the iconic oculomotor and axial symptoms of PSP. These network-level changes provide insights into disease pathophysiology, serve as potential biomarkers, and inform therapeutic strategies.
Litvan I, Mangone CA, McKee A, et al. Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and retrospective validation of the PSP criteria. Ann Neurol. 2002. ↩︎
Whitwell JL, Höglinger GU, Antonini A, et al. 'Radiological biomarkers for diagnosis in PSP: Where are we and where do we go? Mov Disord'. Mov Disord. 2017. ↩︎
Brown CA, Karimi MK, Tian L, et al. Validation of functional imaging of movement disorders in progressive supranuclear palsy. Parkinsonism Relat Disord. 2019. ↩︎
Xia J, Miao Y, Wang J, et al. 'Spontaneous brain activity in progressive supranuclear palsy: A resting-state fMRI study'. J Neurol Sci. 2019. ↩︎
Hue ED, Zhou Y, Xia J, et al. 'Functional connectivity alterations in progressive supranuclear palsy: Resting state fMRI study'. Neurosci Lett. 2018. ↩︎
Filippi M, Basaia S, Sarasso E, et al. Functional brain network changes in progressive supranuclear palsy and Parkinson's disease. Neuroimage Clin. 2019. ↩︎
Tessitore A, Giordano A, Russo A, et al. Salience network dysfunction in progressive supranuclear palsy. J Neurol Neurosurg Psychiatry. 2018. ↩︎
Chen Y, Zhang J, Yang L, et al. Altered functional connectivity of the salience network in progressive supranuclear palsy. J Neuroradiol. 2020. ↩︎
Seeley WW, Crawford R, Rascovsky K, et al. Frontal paralimbic network atrophy in very mild behavioral variant frontotemporal dementia. Arch Neurol. 2008. ↩︎
Prell T, Peschel T, K"ohler B, et al. Structural and functional brain changes in progressive supranuclear palsy. J Neural Transm. 2018. ↩︎
Zhang J, Liu Y, Lan K, et al. 'Disrupted executive network in progressive supranuclear palsy: A resting-state fMRI study'. Neurosci Bull. 2019. ↩︎
Luo C, Chen Y, Song W, et al. Altered resting-state brain activity in progressive supranuclear palsy. Mov Disord. 2018. ↩︎
Niethammer M, Tang CC, Ma Y, et al. Altered brain network topology in progressive supranuclear palsy. J Neurosci. 2018. ↩︎
K"ohler B, Prell T, Peschel T, et al. Basal ganglia dysfunction in progressive supranuclear palsy. Parkinsonism Relat Disord. 2019. ↩︎
Bohnen NI, Albin RL. Cholinergic deficiency hypothesis in progressive supranuclear palsy. Mov Disord. 2019. ↩︎
Padovani A, Borroni B, Brambati SM, et al. Diffusion tensor imaging and voxel-based morphometry in progressive supranuclear palsy. J Neurol Neurosurg Psychiatry. 2006. ↩︎
Robert PH, Mulin E, Mallea P, et al. 'Apathy in progressive supranuclear palsy: Neural correlates and therapeutic implications'. Neurology. 2010. ↩︎
Litvan I, Mega MS, Cummings JL, et al. Neuropsychiatric aspects of progressive supranuclear palsy. Neurology. 1996. ↩︎
McFarland NR, DeBastiani MA, Castro-Sierra E, et al. Thalamic dysfunction in progressive supranuclear palsy. Brain. 2018. ↩︎
Zarei M, Nombela C, Bard JM, et al. Neuroimaging correlates of cognitive impairment in progressive supranuclear palsy. Ann Neurol. 2010. ↩︎
S"anchez-Castaneda C, Squatrito S, Baldacci F, et al. Intralaminar thalamic nuclei involvement in neurodegenerative diseases. Neurology. 2019. ↩︎
Jha M, Jhunjhunwala K, Sankhla CS, et al. Brainstem and cortical dysfunction in progressive supranuclear palsy. Parkinsonism Relat Disord. 2019. ↩︎
Azulay JP, Mesbah S, Bolam JP, et al. 'Ocular motor dysfunction in progressive supranuclear palsy: Neural correlates and therapeutic implications'. Brain. 2019. ↩︎
Kalia LV, Lang AE. Progressive supranuclear palsy and corticobasal degeneration. Lancet Neurol. 2015. ↩︎
Oba H, Yagishita A, Terada H, et al. New and reliable MRI diagnosis for progressive supranuclear palsy. Neurology. 2005. ↩︎
Schroll H, Brien J, Heeger DJ, et al. Serotonergic dysfunction in progressive supranuclear palsy. Brain. 2018. ↩︎
Flabeau O, Meissner WG, Tison F. Sleep and breathing in neurodegenerative disorders. Sleep Med Rev. 2018. ↩︎
Sakamoto K, Matsuda H, Asada T, et al. 'Cerebellar dysfunction in progressive supranuclear palsy: A PET study'. J Neurol. 2019. ↩︎
Cerasa A, Quattrone A. Cerebellar involvement in atypical parkinsonisms. J Neurol Neurosurg Psychiatry. 2016. ↩︎
Filippi M, Basaia S, Sarasso E, et al. Functional brain network changes in progressive supranuclear palsy and Parkinson's disease. Neuroimage Clin. 2019. ↩︎
Wu L, Liu FY, Huang J, et al. 'Altered cerebellar connectivity in Parkinson''s disease and progressive supranuclear palsy: A comparative resting-state fMRI study'. Brain Imaging Behav. 2020. ↩︎
Plant GT, Kaski D. Thalamic dysfunction in movement disorders. Handb Clin Neurol. 2022. ↩︎
Borroni B, Premi E, Agosti C, et al. Structural and functional brain network changes in corticobasal syndrome and progressive supranuclear palsy. Neuroimage Clin. 2019. ↩︎
Hua Y, Zhou J, Wu L, et al. Frontostriatal network dysfunction in corticobasal syndrome compared with progressive supranuclear palsy. J Neurol. 2020. ↩︎
Josephs KA, Whitwell JL, Dickson DW, et al. Voxel-based comparison of progressive supranuclear palsy, corticobasal degeneration and corticobasal syndrome. J Neurol Neurosurg Psychiatry. 2018. ↩︎
Zhou J, Greicius MD, Gennatas ED, et al. Divergent network connectivity changes in behavioural variant frontotemporal dementia and Alzheimer's disease. Brain. 2010. ↩︎
Seeley WW, Crawford R, Zhou J, et al. Neurodegenerative diseases target large-scale human brain functional networks. PLoS Comput Biol. 2009. ↩︎
Zhou J, Seeley WW. 'Network dysfunction in Alzheimer''s disease and frontotemporal dementia: Implications for psychiatry'. Biol Psychiatry. 2014. ↩︎
Sidiropoulos C, Silburn PA, Walter B. 'Pedunculopontine nucleus stimulation for progressive supranuclear palsy: Updated review'. J Neurol Sci. 2019. ↩︎
Li M, Huang L, Yang D, et al. 'Increased thalamocortical connectivity in progressive supranuclear palsy: A resting-state fMRI study'. Neuroradiology. 2020. ↩︎
Whitwell JL, Avula R, Master A, et al. 'Disrupted brain connectivity in Richardson''s syndrome: A 7T MRI study'. Mov Disord. 2021. ↩︎
Yang H, Luo C, Tian L, et al. Longitudinal changes in brain network connectivity in progressive supranuclear palsy. J Neurosci. 2020. ↩︎
Stamelou M, Reich SG, Greener EA. 'Progressive supranuclear palsy: An update'. Curr Neurol Neurosci Rep. 2018. ↩︎
Eggers C, Pedrosa DJ, Kahraman D, et al. 'Brainstem involvement in progressive supranuclear palsy: A diffusion tensor imaging study'. J Neurol. 2019. ↩︎
Lamb R, Rohrer JD, Lees AJ, et al. 'Progressive supranuclear palsy and corticobasal syndrome: Diagnostic challenges and emerging biomarkers'. Nat Rev Neurol. 2020. ↩︎
Odin P, Ray Chaudhuri K, Slevin JT, et al. Collective physician perspectives on non-oral medication approaches for Parkinson's disease management. Parkinsonism Relat Disord. 2015. ↩︎
Bhatti MH, Zhang J, Hou X, et al. Basal ganglia-thalamocortical circuit dysfunction in Richardson's syndrome. Brain Connect. 2019. ↩︎
Mangesius S, Jancke W, Poell B, et al. 'Brainstem network disruption in progressive supranuclear palsy: A graph theory study'. Neuroimage Clin. 2020. ↩︎
Darby RR, Jutkowitz E, Lutz A, et al. Salience network atrophy in progressive supranuclear palsy. Neurology. 2019. ↩︎
Respondek G, Stamelou M, Kurz C, et al. 'The phenotypic spectrum of progressive supranuclear palsy: A retrospective multicenter study of 100 cases'. Mov Disord. 2018. ↩︎
Williams DR, de Silva R, Paviour DC, et al. 'Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson''s syndrome and PSP-parkinsonism'. Brain. 2005. ↩︎
Lopez G, Bayulkem K, Hallett M. 'Progressive supranuclear palsy (PSP): An overview of current understanding'. Tremor Other Hyperkinet Mov (N Y). 2019. ↩︎
Santiago JA, Bottero V, Potashkin JA. Combined evaluation of brain network connectivity and gene expression profiles identifies novel biomarkers for progressive supranuclear palsy. Mol Neurobiol. 2020. ↩︎
Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011. ↩︎
Kertesz A, McMonagle P, Blair M, et al. The evolution and pathology of frontotemporal dementia. Brain. 2005. ↩︎
Williams DR, Lees AJ. 'Progressive supranuclear palsy: Clinicopathological concepts and diagnostic challenges'. Lancet Neurol. 2009. ↩︎
Homayoun N, Simuni T, Bartley S, et al. 'Pure akinesia with gait freezing: A clinical and imaging study'. Mov Disord. 2018. ↩︎
Colosimo C, Osmani A, Kaindl J, et al. 'Pure akinesia with gait freezing: A variant of progressive supranuclear palsy'. Parkinsonism Relat Disord. 2019. ↩︎
Pinsker MO, Volkmann J, Falk D, et al. Deep brain stimulation of the internal globus pallidus for progressive supranuclear palsy. Mov Disord. 2019. ↩︎
Benninger DH, Lomarev M, Wassermann EM, et al. 'Transcranial direct current stimulation for motor and non-motor symptoms of progressive supranuclear palsy: A sham-controlled pilot study'. Neurology. 2020. ↩︎
Stamelou M, Knake S, Oertel WH. Pharmacological management of progressive supranuclear palsy. CNS Drugs. 2019. ↩︎
Bronte-Stewart H, Tatter S, O'Leary K. 'Adaptive neuromodulation for movement disorders: The future is now'. Mov Disord. 2021. ↩︎
Goyal MS, Blakely J, Frosch MP, et al. Tau-targeted immunotherapy for progressive supranuclear palsy. Lancet Neurol. 2022. ↩︎
Kalia LV, Lang AE. 'Movement disorders: What have we learned from cellular models? Lancet Neurol'. Lancet Neurol. 2019. ↩︎